MedTrace Logo

A Study of ALKS 5461 in Healthy Volunteers

NCT02068105 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2014-04-21

No results posted yet for this study

Summary

This is a study to test the safety of ALKS 5461 in healthy adults.

Conditions

  • Pharmacokinetics

Interventions

DRUG

ALKS 5461

Sublingual tablet

DRUG

Placebo

Sublingual tablet

Sponsors & Collaborators

  • Alkermes, Inc.

    lead INDUSTRY

Principal Investigators

  • Randall Marshall, MD · Alkermes, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02068105 on ClinicalTrials.gov